Targeting BET-bromodomains in neuroblastoma
靶向神经母细胞瘤中的 BET-溴结构域
基本信息
- 批准号:9066220
- 负责人:
- 金额:$ 66.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-15 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAcetylationAdultBRD2 geneBindingBinding SitesBiological AssayBiological MarkersBromodomainBypassCancer cell lineCellsChIP-seqChildChildhoodChildhood Extracranial Solid TumorChromatinClinicalClinical TrialsCombined Modality TherapyDNADNA BindingDataDevelopmentDiseaseEZH2 geneEpigenetic ProcessFamily memberFutureGene Expression ProfileGenesGenetic MarkersGenetic TranscriptionGenetically Engineered MouseGenomicsHealthHistonesHumanLinkLysineMYC Family ProteinMYCN geneMalignant Childhood NeoplasmMalignant NeoplasmsMapsMassive Parallel SequencingMeasuresMediator of activation proteinN-Myc ProteinNeuroblastomaOpen Reading FramesPathway interactionsPatientsPharmaceutical PreparationsPolycombProtein Binding DomainProtein MethyltransferasesProto-Oncogene Proteins c-mycPublishingRecruitment ActivityRepressionResistanceResistance developmentRoleRouteSamplingSolid NeoplasmTertiary Protein StructureTestingTissuesTranscription CoactivatorTranscriptional ActivationTranslationsXenograft procedureaurora kinasebasechemotherapychromatin immunoprecipitationchromatin proteinepigenomehigh riskhistone methyltransferasein vivoinhibitor/antagonistmouse modelneuroblastoma cellnew technologypre-clinicalpreclinical trialprogramsprotein complexresearch studyresistance mechanismresponsescreeningsmall hairpin RNAstandard of caretargeted agenttherapy resistanttumor
项目摘要
DESCRIPTION (provided by applicant): MYC transcription factors are frequently dysregulated in cancer. Chromatin-associated protein complexes link MYC to increased histone lysine acetylation in the epigenome. Bromodomain and extraterminal domain (BET) proteins, which bind to these acetylated histone lysines and recruit MYC protein, have therefore emerged as compelling targets in cancer, with inhibitors entering clinical trials. Neuroblastoma is the most common extracranial solid tumor of childhood, with high-risk disease frequently showing Amplification of MYCN. We performed an unbiased screen of diverse cancer cell lines for sensitivity to BET bromodomain inhibitors (BETi). We validated the activity of both BRD4-directed shRNA and BETi against MYCN-amplified neuroblastoma cells, extending these studies in vivo both to patient derived xenografts (PDX) and to genetically engineered mouse (GEM) models of MYCN-driven neuroblastoma. Importantly, while BETi showed remarkable efficacy in vivo, they were not curative, suggesting the need for combination therapies. We hypothesize tat BETi block interactions of MYCN with the epigenetic machinery, and that combination therapies incorporating BETi represent a robust, translatable approach to enhance efficacy, and block emergent resistance in MYCN-driven NB. Our proposal identifies A) Mechanisms through which blockade of MYCN interferes with transformation, B) Mechanisms by which tumors develop resistance to BETi, and C) Translatable combination therapies to block emergent resistance. Successful completion guides effective clinical translation of BETi as pathway-specific inhibitors of MYCN. Aim 1: To clarify a role for EZH2 as a mediator of response to BETi, in MYCN-driven neuroblastoma. Aim 2: To test BETi with EZH2i, and with other translatable combination therapies in preclinical trials in neuroblastoma. Aim 3: To guide development of additional effective combination therapies, by identifying emergent mechanisms for resistance.
描述(由申请人提供):MYC转录因子在癌症中经常失调。染色质相关蛋白复合物将MYC与表观基因组中组蛋白赖氨酸乙酰化增加联系起来。溴结构域和末端外结构域(BET)蛋白结合这些乙酰化组蛋白赖氨酸并募集MYC蛋白,因此已成为癌症中引人注目的靶标,抑制剂进入临床试验。神经母细胞瘤是儿童最常见的颅外实体瘤,高危疾病常表现为MYCN扩增。我们对不同的癌细胞系进行了对BET布罗莫结构域抑制剂(BETi)的敏感性的无偏筛选。我们验证了BRD4定向的shRNA和BETi对MYCN扩增的神经母细胞瘤细胞的活性,将这些体内研究扩展到患者来源的异种移植物(PDX)和MYCN驱动的神经母细胞瘤的基因工程小鼠(GEM)模型。重要的是,虽然BETi在体内显示出显著的疗效,但它们不是治愈性的,这表明需要联合治疗。我们假设BETi阻断MYCN与表观遗传机制的相互作用,并且结合BETi的联合疗法代表了增强疗效的稳健的、可转化的方法,并阻断MYCN驱动的NB中出现的耐药性。我们的提案确定了A)MYCN的阻断干扰转化的机制,B)肿瘤对BETi产生耐药性的机制,以及C)可转化的联合疗法来阻断新出现的耐药性。成功完成指导有效的临床翻译BETi作为MYCN的途径特异性抑制剂。目的1:阐明EZH2在MYCN驱动的神经母细胞瘤中作为对BETi应答的介体的作用。目的2:在神经母细胞瘤的临床前试验中测试BETi与EZH2i以及与其他可转化的组合疗法。目的3:通过确定耐药的紧急机制,指导开发其他有效的联合治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kimberly Stegmaier其他文献
Kimberly Stegmaier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kimberly Stegmaier', 18)}}的其他基金
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
用综合基因组学剖析尤文肉瘤的发病机制
- 批准号:
10064577 - 财政年份:2017
- 资助金额:
$ 66.91万 - 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
- 批准号:
10457896 - 财政年份:2016
- 资助金额:
$ 66.91万 - 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
- 批准号:
10225613 - 财政年份:2016
- 资助金额:
$ 66.91万 - 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
- 批准号:
9981667 - 财政年份:2016
- 资助金额:
$ 66.91万 - 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
- 批准号:
9328023 - 财政年份:2016
- 资助金额:
$ 66.91万 - 项目类别:
Validating Syk as a Target for AML Therapy
验证 Syk 作为 AML 治疗靶点
- 批准号:
8296670 - 财政年份:2009
- 资助金额:
$ 66.91万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 66.91万 - 项目类别: